Licenses lipid nanoparticle delivery technology to drug developers and develops drug candidates for people with chronic hepatitis B.
10-K for FY2025, filed Mar 23, 2026
Collaborators and licensees pay for intellectual-property rights and research and development work through upfront payments, research funding, milestones and royalties.
10-K for FY2025, filed Mar 23, 2026The Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the Company to…View ↗
10-K for FY2025, filed Mar 23, 2026
FY2025 revenue by product or service ↗$14.1M
10-K for FY2025, filed Mar 23, 2026
$14.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaborations and licenses
|
89%
FY2022: 80%
|
Collaborations and licenses, FY2025
$12.6M Sources
|
|
|
Non-cash royalty revenue
Licensed
10-K for FY2025, filed Mar 23, 2026 |
11%
FY2022: 20%
|
Non-cash royalty revenue, FY2025
$1.5M Sources
|
Licensed |
Third parties license its lipid nanoparticle technology for different applications; collaboration agreements also cover research and development services.
10-K for FY2025, filed Mar 23, 2026
No. It lost $33.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
$59.1MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
Growing. Revenue grew 28% in 4 years, from $11M in FY2021 to $14.1M in FY2025, about 6% a year.
Narrower development scope
The older report described hepatitis B programs alongside coronavirus drug research and oncology applications; the latest centers on hepatitis B candidates and lipid nanoparticle technology licensing.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 23, 2026Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company leveraging…View ↗
AB-101 is our oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1.…View ↗
Combining therapeutic product candidates with complementary mechanisms of action to find a functional cure for people with cHBV. We believe…View ↗
Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on…View ↗
Our strategy is focused on maximizing opportunities for our cHBV development programs and, through our exclusive license with Genevant, our…View ↗
In February 2022 and April 2023, we filed patent infringement lawsuits in the United States against Moderna and Pfizer/BioNTech…View ↗
Competes with GSK, Gilead Sciences, Assembly Biosciences, Aligos Therapeutics, AusperBio Therapeutics, Brii Biosciences, Mirum Pharmaceuticals, and Precision Biosciences
10-K for FY2025, filed Mar 23, 2026As a significant unmet medical need exists for HBV, there are several large and small pharmaceutical companies focused on delivering…View ↗
Loading...